UAE approves AstraZeneca’s Baxfendy for hypertension

AstraZeneca has received approval from the EDE in the UAE for Baxfendy, a medicine using the active ingredient baxdrostat, for uncontrolled hypertension. The regulatory approval is supported by data from two Phase III studies, BaxHTN and Bax24. AstraZeneca’s Baxfendy is intended for adults with hypertension. Credit: grandbrothers / Shutterstock.com. AstraZeneca has received approval from the Emirates Drug Establishment (EDE) in the United Arab Emirates (UAE) for Baxfendy, a medicine using the active ingredient baxdrostat, for uncontrolled hypertension. With this authorisation, the UAE is said to become the first nation worldwide to approve this treatment, which is offered in 1mg and…

Source: Pharmaceutical Technology